Advances in nanotechnology-based targeted-contrast agents for computed tomography and magnetic resonance imaging have significantly improved diagnostic capabilities in medical imaging. Traditional contrast agents are limited in their ability to target specific lesions and provide clear differentiation between diseased and healthy tissues. Targeted nano-contrast agents, which leverage the unique properties of nanomaterials such as self-assembly and surface modifiability, offer enhanced targeting and imaging performance. These agents can be designed to improve diagnostic accuracy and sensitivity, particularly in early disease detection. In computed tomography (CT), iodine-based nano-contrast agents, such as nanoliposomes and iodine nanoparticles, have shown promise in enhancing image quality and reducing nephrotoxicity. Gold nanoparticles are also being explored for their high X-ray absorption capacity and potential for multimodal imaging. Other metals like tantalum, tungsten, and bismuth are being studied for their unique properties in CT imaging. In magnetic resonance imaging (MRI), gadolinium-based contrast agents are widely used, but concerns about toxicity and nephrotoxicity have led to the development of functional nano-MRI contrast agents. These agents can improve image contrast and reduce the risk of adverse effects. Superparamagnetic and magnetic nanoparticles are also being investigated for their ability to enhance T1 and T2 weighted imaging. Multimodal nano-contrast agents that combine CT and MRI capabilities are being developed to provide simultaneous imaging in multiple modalities. These agents can enhance diagnostic accuracy and guide therapeutic interventions. Challenges remain in ensuring the safety and biocompatibility of these agents, as well as in optimizing their preparation methods for clinical application. Overall, the development of targeted nano-contrast agents represents a significant advancement in medical imaging, offering improved diagnostic accuracy and therapeutic potential. Continued research is needed to address challenges related to biocompatibility, pharmacokinetics, and clinical application.Advances in nanotechnology-based targeted-contrast agents for computed tomography and magnetic resonance imaging have significantly improved diagnostic capabilities in medical imaging. Traditional contrast agents are limited in their ability to target specific lesions and provide clear differentiation between diseased and healthy tissues. Targeted nano-contrast agents, which leverage the unique properties of nanomaterials such as self-assembly and surface modifiability, offer enhanced targeting and imaging performance. These agents can be designed to improve diagnostic accuracy and sensitivity, particularly in early disease detection. In computed tomography (CT), iodine-based nano-contrast agents, such as nanoliposomes and iodine nanoparticles, have shown promise in enhancing image quality and reducing nephrotoxicity. Gold nanoparticles are also being explored for their high X-ray absorption capacity and potential for multimodal imaging. Other metals like tantalum, tungsten, and bismuth are being studied for their unique properties in CT imaging. In magnetic resonance imaging (MRI), gadolinium-based contrast agents are widely used, but concerns about toxicity and nephrotoxicity have led to the development of functional nano-MRI contrast agents. These agents can improve image contrast and reduce the risk of adverse effects. Superparamagnetic and magnetic nanoparticles are also being investigated for their ability to enhance T1 and T2 weighted imaging. Multimodal nano-contrast agents that combine CT and MRI capabilities are being developed to provide simultaneous imaging in multiple modalities. These agents can enhance diagnostic accuracy and guide therapeutic interventions. Challenges remain in ensuring the safety and biocompatibility of these agents, as well as in optimizing their preparation methods for clinical application. Overall, the development of targeted nano-contrast agents represents a significant advancement in medical imaging, offering improved diagnostic accuracy and therapeutic potential. Continued research is needed to address challenges related to biocompatibility, pharmacokinetics, and clinical application.